keyword
MENU ▼
Read by QxMD icon Read
search

Montelukast allergic rhinitis

keyword
https://www.readbyqxmd.com/read/29079387/management-of-allergic-rhinitis-a-review-for-the-community-pharmacist
#1
REVIEW
J Russell May, William K Dolen
PURPOSE: Allergic rhinitis is a highly prevalent disease affecting the quality of life of millions of North Americans. The management of allergic rhinitis includes allergen avoidance, pharmacotherapy, and immunotherapy. Current pharmacologic options include oral and intranasal antihistamines, intranasal corticosteroids, oral and intranasal decongestants, oral and intranasal anticholinergics, and leukotriene receptor antagonists. Second-generation oral antihistamines and intranasal corticosteroids are the mainstays of treatment, with practice guidelines recommending intranasal corticosteroids as first-line treatment for moderate to severe allergic rhinitis...
October 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29076063/neuropsychiatric-events-associated-with-leukotriene-modifying-agents-a-systematic-review
#2
REVIEW
Sharon W Y Law, Angel Y S Wong, Shweta Anand, Ian C K Wong, Esther W Chan
INTRODUCTION: Leukotriene-modifying agents (LTMAs) including montelukast, zafirlukast, and zileuton are approved by the US Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis. Various neuropsychiatric events (NEs) have been reported; however, the evidence of the association is conflicting. This systematic review investigates the association between NEs and LTMAs by assessing the relevant published literature. METHODS: PubMed, EMBASE, MEDLINE, and Cochrane Library were searched using keywords...
October 26, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29031394/the-role-of-cysteinyl-leukotrienes-and-their-receptors-in-refractory-nasal-polyps
#3
Jintao Du, Luo Ba, Jiao Zhou, Lingyu Yu, Ruowu Liu, Jie Zhang, Feng Liu, Junming Xian, Shixi Liu, Yafeng Liu
Leukotriene signaling is essential in many diseases, including asthma, allergic rhinitis, atherosclerosis and inflammatory bowel disease. Nevertheless, the expression of cysteinyl leukotrienes (CysLTs) and its receptors (CYSLTRs) in different types of nasal polyps (NPs), and the role of their antagonist in the treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) are not well understood. The following study investigates the expression of CysLTs and CYSLTRs in different types of NPs, as well as the role of leukotriene receptor antagonist (montelukast) in refractory NPs...
November 2017: Prostaglandins, Leukotrienes, and Essential Fatty Acids
https://www.readbyqxmd.com/read/28851715/oesophageal-mastocytosis-eosinophilic-oesophagitis-without-eosinophils
#4
Donevan Westerveld, Jian Li, Sarah Glover
A 59-year-old male with a history of lifelong asthma, allergic rhinitis and hypercholesterolaemia presented to the emergency department for management of severe substernal chest pain with radiating pain to his left arm, nausea and diaphoresis. Physical examination was unrevealing and a cardiac workup including cardiac enzymes, ECG, chest radiographs were negative for an underlying ischaemic event. A subsequent gastrointestinal workup including oesophageal manometry and oesophagogastroduodenoscopy revealed elevated lower oesophageal pressures and histopathology suggestive of mast cell proliferation, respectively...
August 28, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28639856/adverse-events-are-rare-after-single-dose-montelukast-exposures-in-children
#5
Donald H Arnold, Nena Bowman, Theodore F Reiss, Tina V Hartert, Donna L Seger
STUDY OBJECTIVE: Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults. We sought to characterize adverse events associated with single montelukast exposures in children ages 5-17 years and to determine whether adverse events were dose related for all-dose and for ultra-high-dose (≥50 mg) exposures. METHODS: This is a retrospective analysis of data from the National Poison Data System for exposures that included montelukast in individuals aged 5-17 years for calendar years 2000-2016...
June 22, 2017: Clinical Toxicology
https://www.readbyqxmd.com/read/28639121/montelukast-use-a-19-year-nationwide-drug-utilisation-study
#6
Daniel Pilsgaard Henriksen, Jesper Rømhild Davidsen, Christian B Laursen, Anders Christiansen, Per Damkier, Jesper Hallas, Anton Pottegård
PURPOSE: Montelukast is a leukotriene receptor antagonist used in asthma and rhinitis treatment. Despite being marketed nearly two decades ago, little is known about its utilisation pattern. METHODS: Using the Danish National Prescription Registry, we identified subjects filling a montelukast prescription between 1998 and 2017. Using descriptive statistics, we reported the development in incidence, and prevalence, as well as a measure of treatment duration, and concomitant use of asthma- or anti-allergic therapy...
June 22, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28374082/the-leukotriene-receptor-antagonist-montelukast-and-its-possible-role-in-the-cardiovascular-field
#7
REVIEW
Malvina Hoxha, G Enrico Rovati, Aurora Bueno Cavanillas
BACKGROUND: Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are pro-inflammatory mediators of the 5-lipooxygenase (5-LO) pathway, that play an important role in bronchoconstriction, but can also enhance endothelial cell permeability and myocardial contractility, and are involved in many other inflammatory conditions. In the late 1990s, leukotriene receptor antagonists (LTRAs) were introduced in therapy for asthma and later on, approved for the relief of the symptoms of allergic rhinitis, chronic obstructive pulmonary disease, and urticaria...
July 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28294420/chronic-urticaria-in-the-real-life-clinical-practice-setting-in-sweden-norway-and-denmark-baseline-results-from-the-non-interventional-multicentre-aware-study
#8
S F Thomsen, E C Pritzier, C D Anderson, N Vaugelade-Baust, R Dodge, A-K Dahlborn, C Vestergaard
BACKGROUND: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28109729/comparison-of-the-effects-of-nasal-steroids-and-montelukast-on-olfactory-functions-in-patients-with-allergic-rhinitis
#9
A Dalgic, M E Dinc, S Ulusoy, D Dizdar, A Is, M Topak
OBJECTIVE: Olfactory dysfunction is one of the comorbidities associated with allergic rhinitis (AR) and AR is one of the common causes of olfactory problems. We aimed to evaluate by the Sniffin' Sticks test the effects on olfactory functions of nasal steroids and leukotriene antagonists used for allergic rhinitis. METHODS: Thirty patients with seasonal rhinitis were included in this study. Patients were randomly divided into three groups of 10 patients; group 1 received montelukast sodium and mometasone furoate (MF) therapy, group 2 received only montelukast, and group 3 only MF...
September 2017: European Annals of Otorhinolaryngology, Head and Neck Diseases
https://www.readbyqxmd.com/read/28066101/comparison-of-efficacy-safety-and-cost-effectiveness-of-montelukast-levocetirizine-and-montelukast-fexofenadine-in-patients-of-allergic-rhinitis-a-randomized-double-blind-clinical-trial
#10
RANDOMIZED CONTROLLED TRIAL
Mohini Sachin Mahatme, Ganesh Natthuji Dakhale, Kanchan Tadke, Sachin Keshaorao Hiware, S D Dudhgaonkar, Sumit Wankhede
OBJECTIVES: Allergic rhinitis (AR) is a global health problem. Almost 10%-25% of population worldwide is affected by AR. Oral/intranasal H1-antihistamine, decongestants, leukotriene receptor antagonists, and intranasal corticosteroids are the pillars in the management of AR. The combination therapy of montelukast with antihistaminic provides enhancing and complimentary effects, thereby reducing the symptoms effectively, but there are scanty data regarding the comparisons of combinations...
November 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27826703/leukotriene-receptor-antagonists-and-antiallergy-drugs
#11
REVIEW
Tsutomu Tamada, Masakazu Ichinose
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRAs) are known to be useful for long-term management of asthma patients complicated by allergic rhinitis (AR) or exercise-induced asthma (EIA). Currently available LTRAs are pranlukast hydrate, zafirlukast, and montelukast. These LTRAs have a bronchodilator action and inhibit airway inflammation, resulting in a significant improvement of asthma symptoms, respiratory function, inhalation frequency of as-needed inhaled β2-agonist, airway inflammation, airway hyperresponsiveness, dosage of ICSs, asthma exacerbations, and patients' QOL...
2017: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27785374/montelukast-in-the-treatment-of-perennial-allergic-rhinitis-in-paediatric-japanese-patients-an-open-label-clinical-trial
#12
Kimihiro Okubo, Yoichi Inoue, Hirotaka Numaguchi, Kumi Tanaka, Itori Saito, Nobuyuki Oshima, Yuki Matsumoto, Marita Prohn, Anish Mehta, Chisato Nishida, George Philip
Background: This study was conducted to evaluate the safety and tolerability, and population pharmacokinetics (PPK) of montelukast as well as efficacy in the treatment of perennial allergic rhinitis (PAR) in paediatric Japanese patients aged between 1 and 15 years. Methods: In this multi-centre, open-label trial, 87 paediatric Japanese patients with PAR received montelukast 4 mg oral granules (OG) for 4 weeks (1-5-year-olds, N = 15), 4 mg OG for 12 weeks (1-5-year-olds, N = 36), 5 mg chewable tablets (CT) for 12 weeks (6-9-year-olds, N = 18), or 5 mg CT for12 weeks (10-15-year-olds, N = 18)...
2016: Journal of drug assessment
https://www.readbyqxmd.com/read/27764975/early-patient-experiences-with-montelukast-orally-disintegrating-tablets-in-japan-a-cross-sectional-survey-of-treatment-satisfaction-in-patients-with-asthma-and-or-allergic-rhinitis
#13
Diane Whalley, Tanaz Petigara, Lawrence Rasouliyan, Keisuke Tobe, Kaan Tunceli
OBJECTIVE: Orally disintegrating tablets (ODTs) offer a valuable treatment option, particularly when swallowing solid tablets with water is difficult or inconvenient. Montelukast is an effective treatment for asthma and allergic rhinitis (AR), and an ODT formulation became available in Japan in 2015. This study investigated levels of satisfaction with this new formulation among adults with asthma and/or AR in Japan. METHODS: Patients aged 20 years or older who were refilling a prescription for montelukast ODT in pharmacies across Japan completed questions on satisfaction with key features of montelukast ODT and the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)...
February 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27527264/treatment-effect-of-sublingual-immunotherapy-tablets-and-pharmacotherapies-for-seasonal-and-perennial-allergic-rhinitis-pooled-analyses
#14
COMPARATIVE STUDY
Stephen R Durham, Peter S Creticos, Harold S Nelson, Ziliang Li, Amarjot Kaur, Eli O Meltzer, Hendrik Nolte
BACKGROUND: Data comparing the treatment effect of allergy immunotherapy and pharmacotherapy are lacking. OBJECTIVE: We sought to indirectly compare the treatment effect of sublingual immunotherapy (SLIT)-tablets with pharmacotherapy for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). METHODS: Pooled data from randomized, double-blind, placebo-controlled trials for the clinical development programs of selected allergic rhinitis treatments were evaluated...
October 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27522261/the-efficacy-and-safety-of-h1-antihistamine-versus-montelukast-for-allergic-rhinitis-a-systematic-review-and-meta-analysis
#15
REVIEW
Chunhui Wei
PURPOSE: In order to verify the differences of effectiveness and safety between SAHs and Montelukast, and to find out potential uncared-for problems, we performed a systematic review and Meta-analysis to proceed a qualitative describe and quantitative assessment. METHODS: We searched the databases of Pubmed, the Cochrane Library, Nature and Science as well as Wanfang data and CNKI from 2000 to March 2016, using key words "Montelukast SAH" or "H1-antihistamine Montelukast", or "Loratadine Montelukast", or "Desloratadine Montelukast", or "Levocetirizine Montelukast", or "Cetirizen Montelukast", or "Fexofenadine Montelukast"...
October 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27485393/montelukast-current-indications-and-prospective-future-applications
#16
Naim Kittana, Suhaib Hattab, Azza Ziyadeh-Isleem, Nidal Jaradat, Abdel-Naser Zaid
INTRODUCTION: Montelukast is recommended for the treatment of asthma, exercise -induced bronchospasm and allergic rhinitis. Several trials demonstrated potential therapeutic effects in other respiratory conditions, and different animal-model-based studies explored potential pharmacological actions in non-respiratory conditions. AREAS COVERED: Clinical investigations on the pharmacotherapeutic effects of montelukast, in addition to in-vivo studies on animal models of non-respiratory diseases...
September 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/27152482/predictors-of-asthma-following-severe-respiratory-syncytial-virus-rsv-bronchiolitis-in-early-childhood
#17
Susan Lu, Tina V Hartert, Mark L Everard, Hilde Giezek, Linda Nelsen, Anish Mehta, Hima Patel, Barbara Knorr, Theodore F Reiss
BACKGROUND: We sought to identify predictors of asthma development following severe early childhood RSV bronchiolitis. Different definitions of asthma were also compared. METHODS: This longitudinal, observational study (N = 343) followed patients (<2 years old) from a placebo-controlled trial (N = 979) of montelukast after RSV bronchiolitis to identify clinical, demographic, or biochemical predictors of asthma, atopic disorders, and chronic asthma therapy use at 6 years of age (Clinical Trials Registry Number: NCT01140048)...
December 2016: Pediatric Pulmonology
https://www.readbyqxmd.com/read/27101674/-clinical-evaluation-of-montelukast-plus-budesonide-nasal-spray-and-desloratadine-citrate-disodium-in-treating-moderate-and-severe-persistent-allergic-rhinitis
#18
RANDOMIZED CONTROLLED TRIAL
Renzia Wang, Chunhui Zhang
OBJECTIVE: To investigate the clinical efficacy of montelukast plus budesonide nasal spray and desloratadine citrate disodium tablets on moderate and severe persistent allergic rhinitis. METHOD: Senenty patients with moderate and severe persistent allergic rhinitis were devided randomly study group (n = 35) and control group (n = 35). The study group were treated with montelukast sodium tablets combined with budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks, the control group received budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks...
December 2015: Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery
https://www.readbyqxmd.com/read/27084419/minimal-clinically-important-difference-mcid-in-allergic-rhinitis-agency-for-healthcare-research-and-quality-or-anchor-based-thresholds
#19
Eli O Meltzer, Dana Wallace, Mark Dykewicz, Lucy Shneyer
BACKGROUND: In 2013, the Agency for Healthcare Research and Quality (AHRQ) recommended that allergic rhinitis (AR) studies calculate a minimal clinically important difference (MCID) based on an estimated threshold equal to 30% of the maximum total nasal symptom score. Applying this threshold, their data showed no differences between well-established treatments, and a subsequent analysis using prescribing information found no differences between active treatments and placebo controls. OBJECTIVE: The objective of this study was to demonstrate the application of an evidence-based model to determine MCIDs for AR studies, with an absolute value for an anchor-based threshold and validated methods for calculating distribution-based thresholds...
July 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/26922938/a-case-of-pranlukast-induced-anaphylactic-shock
#20
Sujeong Kim, Jong Myung Lee
Leukotriene receptor antagonists, which are generally considered safe with a few adverse drug reactions, are increasingly used in the treatment of various allergic diseases, including asthma and allergic rhinitis. Although a few anaphylactic reactions to montelukast have been reported worldwide, there is still a lack of reports about severe adverse drug reactions associated with pranlukast. Here, we report a case of severe hypersensitivity reaction associated with pranlukast. A 65-year-old woman developed anaphylactic shock that presented as generalized urticaria, angioedema, collapse, and loss of consciousness after receiving pranlukast...
May 2016: Allergy, Asthma & Immunology Research
keyword
keyword
33627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"